Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 20/20 | 0.59 |
| ▸ | HTR1A | P08908 | 1/20 | 0.53 |
| ▸ | DRD2 | P14416 | 1/20 | 0.53 |
| ▸ | HTR1D | P28221 | 1/20 | 0.53 |
| ▸ | HTR1B | P28222 | 1/20 | 0.53 |
| ▸ | HTR1F | P30939 | 1/20 | 0.53 |
| ▸ | HTR7 | P34969 | 1/20 | 0.53 |
| ▸ | DRD3 | P35462 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4046291 | 0.89 | HTR6 (0.74) | HTR6HTR1ADRD2HTR1DHTR1B | |
| SCHEMBL4045887 | 0.88 | HTR6 (0.68) | HTR6HTR1ADRD2HTR1DHTR1B | |
| SCHEMBL4047390 | 0.88 | HTR6 (0.68) | HTR6HTR1ADRD2HTR1DHTR1B | |
| SCHEMBL4052627 | 0.78 | HTR6 (0.71) | HTR6 | |
| SCHEMBL3582405 | 0.75 | HTR6 (0.53) | HTR6HTR1ADRD2HTR1DHTR1B | |
| SCHEMBL3603964 | 0.74 | HTR6 (0.52) | HTR6HTR1ADRD2HTR1DHTR1B | |
| SCHEMBL5229572 | 0.72 | HTR6 (0.70) | HTR6HTR1ADRD2HTR1DHTR1B | |
| SCHEMBL5276037 | 0.71 | HTR6 (0.47) | HTR6 | |
| SCHEMBL14953611 | 0.71 | HTR6 (0.42) | HTR6HTR7 | |
| SCHEMBL3936879 | 0.71 | HTR6 (0.41) | HTR6HTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1856132-B1 | PROCESS FOR PREPARING SUBSTITUTED BENZOTHIAZINOINDOLES | SUVEN LIFE SCIENCES LTD (IN) | 2009-04-01 | — | — | EP | disclosed |
| US-20080119646-A1 | Process for Preparing Substituted Benzothiazinoindoles | SUVEN LIFE SCIENCES LIMITED (IN) | 2008-05-22 | — | — | US | disclosed |
| EP-1856132-A1 | PROCESS FOR PREPARING SUBSTITUTED BENZOTHIAZINOINDOLES | Suven Life Sciences Limited (IN) | 2007-11-21 | — | — | EP | disclosed |
| WO-2006095360-A1 | PROCESS FOR PREPARING SUBSTITUTED BENZOTHIAZINOINDOLES | SUVEN LIFE SCIENCES LIMITED (IN) | 2006-09-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119646-A1 | Process for Preparing Substituted Benzothiazinoindoles | C5, CYP8B1, CBR1 | HTR6 698/4885HTR1A 488/4885DRD2 962/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.